Popular Oncogene News and Current Events | Page 2

Popular Oncogene News and Current Events, Oncogene News Articles.
Sort By: Most Relevant | Most Recent
Page 2 of 14 | 528 Results
Long thought harmless, a glycan biomarker may cause pancreatic disease and cancer
A widely recognized biomarker for pancreatic disease, CA19-9, thought to be benign for decades, may in fact be a promoter for the development of these diseases, including pancreatic cancer. (2019-06-20)

Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
Researchers from the Children's Cancer Hospital at the University of Texas M. D. Anderson Cancer Center have discovered a new drug combination that significantly hinders tumor growth in neuroblastoma, a childhood cancer. The study was presented today at the 22nd Annual Meeting of the American Society of Pediatric Hematology/Oncology. (2009-04-24)

An effective target of biological therapy for hepatocellular carcinoma
A research group in China applied a DNA vector-based STAT3-specific RNA interfering approach to block STAT3 signaling and to evaluate the biological consequences of STAT3 down-modulation on tumor growth using a tumor-bearing nude mice model. Silencing of STAT3 by RNAi suppresses tumor growth in vivo and STAT3 may act as an effective target for HCC therapy. (2009-06-12)

Researchers use computer model to predict prostate cancer progression
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the course of disease for prostate cancer. The model is currently being implemented at a prostate cancer clinic in Germany. The researchers have also found the enzyme that appears to trigger some of the first mutations in prostate cancer. (2018-12-11)

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals. Their findings, which have now been published in the journal 'Proceedings of the National Academy of Sciences U.S.A.', explain why promising anti-CDK8 drugs are only effective under laboratory conditions but likely not in humans. Gained results also show a new way of developing CDK8-specific drugs in the future. (2020-01-28)

Discovered a molecule that regulates the development of cancer in a variety of tumors
Researchers from the Josep Carreras Leukemia Research Institute (IJC), discover that a non-coding region of the genome originates a key molecule for the proliferation of tumors in breast cancer and some types of sarcoma. (2019-09-04)

Researchers discover a tumor suppressor gene in a very aggressive lung cancer
The Genes and Cancer Group at the Cancer Epigenetics and Biology Program of the IDIBELL has found that the MAX gene, which encodes a partner of the MYC oncogene, is genetically inactivated in small cell lung cancer. Reconstitution of MAX significantly reduced cell growth in the MAX-deficient cancer cell lines. These findings show that MAX acts as a tumor suppressor gene in one of the more aggressive types of lung cancer. (2014-01-09)

Disarming specialized stem cells might combat deadly ovarian cancer
Eliminating cancer stem cells (CSCs) within a tumor could hold the key to successful treatments for ovarian cancer, which has been notoriously difficult to detect and treat, according to new findings published this week in the journal Oncogene by Yale School of Medicine researchers. (2010-01-27)

Blood tumor markers may warn when lung cancer patients are progressing
University of Colorado Cancer Center study suggests that rather than screening for disease, blood tumor markers could be useful in monitoring therapeutic outcomes in those with already established disease. (2017-09-06)

Virus- and oncogene-free reprogramming method for the production of iPSCs published in the journal
Regenerative Medicine is delighted to publish open access original research demonstrating the first virus- and oncogene-free induced pluripotent stem cell (iPSC) technology to produce safer pluripotent stem cells from cord blood and peripheral blood. (2018-12-06)

An epigenetic lesion could be responsible for acute T-cell leukemia
Researchers from the Epigenetics and Cancer Biology Program (PEBC) led by Dr. Manel Esteller at IDIBELL have discovered how an epigenetic lesion can lead to T-cell acute lymphoblastic leukemia. The article, published in the journal Leukemia, correlates the lesion with the activation of a powerful oncogen capable of malignizing this type of cells of the immune system. (2017-03-30)

How newly found tension sensor plays integral role in aligned chromosome partitioning
A Waseda University-led research found that oncogene SET/TAF1, which was found to be a proto-oncogene of acute myeloid leukemia (AML), contributes to proper chromosome partitioning as a tension sensor. Additionally, abnormal SET protein disrupts tension sensor system at the centromere, leading to missegregation of the chromosomes and thereby cancer. These findings may lead to a discovery for a new kind of leukemia treatment. (2019-09-30)

Bacterial degradation of the MYC oncogene -- a new cancer treatment strategy?
Scientists at Lund University have discovered how E. coli bacteria target and degrade the well-known oncogene MYC, which is involved in many forms of cancer. The study is now published in Nature Biotechnology. (2021-02-12)

Genetic cause identified in rare pediatric brain tumor
Researchers found a way of differentiating angiocentric gliomas from other low-grade pediatric brain tumors and developed a pathological test that will help children avoid unnecessary and potentially damaging additional therapies. (2016-02-01)

Caution needed for drugs in development for most common malignant pediatric brain tumor
Researchers at St. Jude Children's Research Hospital have studied how a crucial cancer-related protein plays a role in one of the most aggressive forms of medulloblastoma, the most common malignant brain tumor of childhood. (2017-03-21)

Tiny RNA has big impact on lung cancer tumors
Researchers from Yale University and Mirna Therapeutics Inc., reversed the growth of lung tumors in mice using a naturally occurring tumor suppressor microRNA. The study reveals that a tiny bit of RNA may one day play a big role in cancer treatment, and provides hope for future patients battling one of the most prevalent and difficult to treat cancers. (2009-12-07)

A protein, a 'molecular staple' and CRISPR to develop an Ewing sarcoma model
A team from the Spanish National Cancer Research Centre (CNIO) has optimized a system capable of generating a cellular model of Ewing sarcoma. The technique, based on CRISPR and described in the pages of Stem Cell Reports, makes it possible to generate cellular models to analyze the mechanisms underlying the origin and progression of this and other diseases, as well as the search for new treatments. (2017-05-10)

Breast cancer discovery could help stop disease's deadly spread
Researchers have identified a gene responsible for the spread of triple-negative breast cancer to other parts of the body and developed a potential way to stop it. (2020-11-20)

CSHL team develops mouse models of leukemia that predict response to chemotherapy
Researchers led by Professor Scott Lowe, Ph.D., of Cold Spring Harbor Laboratory have designed new mouse models of human acute myeloid leukemia that accurately predict chemotherapy response in patients. The models precisely recapitulate genetic associations that have been linked to favorable or adverse treatment responses in patients and help identify genes promoting resistance or sensitivity to any cancer drug. The models are also an effective test system for new drugs and treatment strategies for AML. (2009-03-31)

Drug combination shows benefit in RAS-driven cancers
Dana-Farber Cancer Institute scientists report a number of patients in a small study with RAS-driven lung, ovarian, and thyroid cancers got long-term clinical benefit from a combination of two drugs that targeted molecular pathways controlled by the RAS gene. (2017-04-03)

New study explains how inflammation causes gastric cancer
Researchers from Kanazawa University and the Japan Agency for Medical Research and Development have solved the decades-old mystery of how stomach bacterium Helicobacter pylori causes gastric cancer. Using mouse models and human cancer cell lines, they showed that inflammation resulting from bacterial infection leads to the proliferation of gastric epithelial cells, which ultimately form gastric tumors. By blocking the protein pathway responsible for this proliferation, they prevented gastric tumor formation. (2019-04-16)

Advanced prostate cancer has an unexpected weakness that can be targeted by drugs
Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cells in vitro and in vivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs. (2020-10-07)

Mayo Clinic researchers find oncogene is important in pancreatic cancer growth and spread
Researchers at the Mayo Clinic campus in Florida have found that PKC-iota (PKC-i), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. They also found that genetically inhibiting PKC-i in laboratory animals led to a significant decrease in pancreatic tumor growth and spread. (2010-02-23)

'Druggable' protein complex identified as a therapeutic target in acute myeloid leukemia
Scientists at Cold Spring Harbor Laboratory have identified a candidate drug target for treating acute myeloid leukemia, a white blood cell cancer that proliferates out of control in the bone marrow. The team, led by Assistant Professor Chris Vakoc, M.D., Ph.D., shows that blocking a protein called PRC2 halts this uncontrolled proliferation in the bone marrow of mice with AML. (2012-04-02)

Prolactin blocks oncogene associated with poor prognosis in breast cancer
Researchers from the Kimmel Cancer Center at Jefferson have found a mechanism by which a hormone responsible for milk production blocks an oncogene that makes breast cancer more aggressive. (2010-02-03)

NFCR-supported scientists discover key factor in brain cancer resistance
Researchers at the NFCR Center for Cancer System Informatics at MD Anderson Cancer Center have discovered a key factor that may explain drug resistance in glioblastoma, the most common and deadliest form of brain cancer. (2015-04-20)

Reprogramming bone tumors
There exist several oncogenes that drive cancer. In many cases, however, the oncogenes themselves are not sufficient and must be complemented with other mutations before cancer develops. Researchers at the Center for iPS Cell Research and Application, Kyoto University, use cell reprogramming technology to revert cancer cells to a stem cell state. The researchers show that dysfunctional differentiation in conjunction with a specific oncogene could explain the cause of certain bone cancers. (2016-03-17)

UCLA study shows inhibition of gene helps overcome resistance to immunotherapy
A new study helps explain why some people with advanced cancer may not respond to one of the leading immunotherapies, PD-1 blockade, and how a new combination approach may help overcome resistance to the immunotherapy drug. (2019-12-09)

New finding points to potential options for attacking stem cells in triple-negative breast cancer
New research finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease. (2014-02-17)

Stirring up conflicts in tumour cells
With two commercially available inhibitors, the cell cycle of the cancer cells in the childhood tumour neuroblastoma can be disrupted at a key point causing tumour cell death. (2021-02-11)

Ovarian cancer target molecule may be key to blocking its spread
Blocking a protein found on the surface of ovarian cancer cells could prevent or reduce the spread of the disease to other organs, according to new research at the University of Illinois at Chicago. (2017-03-01)

Discovery of a new gene critical in the development of lung and pancreatic cancers
Researchers at the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have identified a critical gene, FOSL1, in the development of lung and pancreatic cancer. The work, published in Nature Communications, shows that the inhibition of FOSL1 brings about a great reduction in the size of the tumors in the lungs and pancreas. Thus, the results present this gene as a new molecular target to which new drugs should be directed. (2017-02-21)

Inverted DNA turns quiet developmental gene into a potent driver of t-cell lymphoma
A chromosomal flip turns a gene crucial for embryonic development into a potent promoter of lymphoma in adult mice, according to researchers from Fox Chase Cancer Center. A gene called Dlx5 works cooperatively with a known oncogene, Akt2, to drive cancer in white blood cells. Since Akt2 has proven a difficult target to block safely, the Dlx5 protein could be a safer target for drugs to slow the growth of human lymphomas and other cancers. (2008-02-27)

'Hijacker' drives cancer in some patients with high-risk neuroblastoma
Researchers in Memphis and Boston have collaborated to show c-MYC is an oncogene that drives neuroblastoma in some high-risk patients; the findings help set the stage for much-needed precision medicines (2018-01-22)

Silencing RNA nanotherapy shows promise against pancreatic cancer
Despite advances in cancer survival, more than 90% of people with pancreatic cancer die within five years. Now a preclinical study by Washington University School of Medicine in St. Louis, and the University of South Florida Morsani College of Medicine, Tampa, Fla., has demonstrated that specially designed peptide-based nanoparticles can suppress pancreatic cancer growth without the toxic side effects and therapeutic resistance seen in drug trials. (2019-10-21)

University of South Carolina researchers discover new subtype of cervical cancer
Scientists from the University of South Carolina have identified a new subtype of cervical cancer that may explain why a fraction of cervical cancer patients do not respond to standard treatment. (2017-01-10)

CNIO finds a possible new pharmacological target for one of the most important and elusive oncogenes
MYC is altered in more than half of human cancers, and it is often associated with very aggressive tumors. Researchers have identified a second gene, called BPTF, that has an important role in the chain of molecular events that allow MYC to function, therefore revealing itself as a possible new therapeutic target. (2016-01-05)

Oncoproteins interact to promote cancer cell growth in retinoblastoma
Researchers at The Saban Research Institute of Children's Hospital Los Angeles have identified an unsuspected and critical role of the MDM2 oncogene in promoting expression of the MYCN oncogene that is required for growth and survival of retinoblastoma cells. Their results are published in the Oct. 17 online edition of the Nature journal Oncogene. (2016-10-17)

Massachusetts General researchers identify new target for cancer immunotherapy
Massachusetts General Hospital investigators have found new evidence that the tumor necrosis factor receptor type II may be a major target for immuno-oncology treatments, which induce a patient's immune system to fight cancer. (2017-01-17)

When green means stop
Optogenetics has revolutionized how researchers investigate cellular behavior and the function of large and interconnected tissues such as the brain. This successful combination of optics and genetics is powered by light-sensitive proteins, many of which have been engineered to bind to each other upon light stimulation. Scientists at IST Austria now expanded the optogenetic protein toolbox. They engineered a receptor that releases binding in green light. This avoids bleaching and toxic side effects of light. (2017-03-22)

Page 2 of 14 | 528 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.